ESH AL 2018 | Benefits of MRD use in ALL

Name: Benefits of MRD use in ALL
Uploaded: 2018-05-04T00:00:00.000Z
Duration: 50 s
Description: In this interview, Torsten Haferlach, MD, of MLL Munich Leukemia Laboratory, Munich, Germany, comments on the benefits of the use of measurable residual disease (MRD) to inform treatment decisions rather than having to rely on morphology assessments. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.

Torsten Haferlach • 4 May 2018

ESH AL 2018

Acute Lymphoblastic Leukemia Leukemia

In this interview, Torsten Haferlach, MD, of MLL Munich Leukemia Laboratory, Munich, Germany, comments on the benefits of the use of measurable residual disease (MRD) to inform treatment decisions rather than having to rely on morphology assessments. This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.